Calamos Advisors LLC lowered its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 55.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,768 shares of the company’s stock after selling 42,210 shares during the quarter. Calamos Advisors LLC’s holdings in Astrazeneca were worth $6,660,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Triumph Capital Management acquired a new position in Astrazeneca in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca during the fourth quarter worth $26,000. Mascoma Wealth Management LLC acquired a new stake in shares of Astrazeneca during the first quarter worth $26,000. Bangor Savings Bank grew its position in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca in the fourth quarter valued at $30,000. 20.35% of the stock is owned by hedge funds and other institutional investors.
Key Astrazeneca News
Here are the key news stories impacting Astrazeneca this week:
- Negative Sentiment: AstraZeneca is facing investor-law-firm investigations after the Wainua trial miss and the related stock drop, adding headline risk and potential litigation over alleged securities claims. Article Title
- Negative Sentiment: HSBC downgraded AstraZeneca and lowered its price target after the Wainua setback, saying the failure removes a central support for the company’s bullish outlook and leaves a tougher catalyst path ahead. Article Title
- Negative Sentiment: A second investor alert from Levi & Korsinsky highlighted the Wainua phase 3 miss and encouraged shareholders to seek recovery of losses, reinforcing the negative sentiment around the trial failure. Article Title
- Neutral Sentiment: UBS remained constructive ahead of AstraZeneca’s second-quarter results, saying it expects solid earnings but limited room for full-year guidance increases. Article Title
- Positive Sentiment: AstraZeneca also announced an exclusive global licensing deal for a lung-cancer pill from China’s Dizal Pharmaceutical, paying $600 million upfront with up to $900 million in milestones. The deal could strengthen its oncology pipeline and supports longer-term growth. Article Title
Astrazeneca Price Performance
Astrazeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. As a group, analysts predict that Astrazeneca Plc will post 10.28 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the company. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.
View Our Latest Analysis on AZN
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
